Search results (1320)
« Back to PublicationsTHE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Vannucchi A. et al, (2021), HAEMATOLOGICA, 106, 51 - 51
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF. et al, (2021), Blood Adv, 5, 3387 - 3396
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Roy A. et al, (2021), Cell Rep, 36
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.
Iskander D. et al, (2021), Sci Transl Med, 13
Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta V. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S362 - S362
CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker U. et al, (2021), ONCOLOGY RESEARCH AND TREATMENT, 44, 158 - 158
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O. et al, (2021), Br J Haematol, 194, 1010 - 1015
Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Mesa R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S360 - S360
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
Lim SH. et al, (2021), Lancet Haematol, 8, e542 - e544
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Zhang X-Y. et al, (2021), Br J Haematol, 194, 508 - 517
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Frangou E. et al, (2021), Gynecol Oncol, 162, 431 - 439
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI. et al, (2021), Br J Cancer, 125, 520 - 527
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA. et al, (2021), Leukemia, 35, 2424 - 2430
Sequencing therapies in Hodgkin lymphoma.
Phillips EH. et al, (2021), Lancet Haematol, 8, e537 - e539
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP. et al, (2021), Blood Adv, 5, 2852 - 2862
The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.
Mughal TI. et al, (2021), Haematologica, 106, 1787 - 1793
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.
Harrington K. et al, (2021), CANCER RESEARCH, 81
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N. et al, (2021), Adv Ther, 38, 3789 - 3802